Log in

NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News

$0.93
+0.01 (+1.09 %)
(As of 04/7/2020 08:33 AM ET)
Add
Compare
Today's Range
$0.90
Now: $0.93
$0.98
50-Day Range
$0.92
MA: $1.50
$2.48
52-Week Range
$0.90
Now: $0.93
$4.97
Volume2.71 million shs
Average Volume4.25 million shs
Market Capitalization$251.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94
TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Read More
TherapeuticsMD logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.65 million
Book Value$0.03 per share

Profitability

Net Income$-176,150,000.00
Net Margins-354.79%

Miscellaneous

Employees241
Market Cap$251.46 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

How has TherapeuticsMD's stock been impacted by COVID-19 (Coronavirus)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TXMD shares have decreased by 39.1% and is now trading at $0.9261. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for TherapeuticsMD.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings results on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The firm had revenue of $15.90 million for the quarter, compared to the consensus estimate of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,170.63%. TherapeuticsMD's revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. View TherapeuticsMD's earnings history.

What guidance has TherapeuticsMD issued on next quarter's earnings?

TherapeuticsMD issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, March, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11 million, compared to the consensus revenue estimate of $11.64 million.

What price target have analysts set for TXMD?

9 brokerages have issued 1-year price objectives for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 871.8% from the stock's current price. View analysts' price targets for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

News coverage about TXMD stock has been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutTherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), Inovio Pharmaceuticals (INO), Horizon Therapeutics (HZNP), Micron Technology (MU) and Novavax (NVAX).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $0.93.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $251.46 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe. View additional information about TherapeuticsMD.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel